Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy

Kevin Emery Boczar MD1, Olexiy Aseyev MD PhD2, Jeffrey Sulpher MD FRCPC2, Christopher Johnson MD FRCPC3, Ian G Burwash MD FRCPC1, Michele Turek MD FRCPC2, Susan Dent MD FRCPC2 and Girish Dwivedi DM PhD (UK) MRCP (UK)1

1Department of Medicine (Cardiology), University of Ottawa Heart Institute, Ottawa, Ontario, Canada
2Department of Medicine (Oncology), The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
3Department of Medicine (Cardiology), The Ottawa Hospital, Ottawa, Ontario, Canada

Abstract

Background: Cardiotoxicity from anthracycline-based chemotherapy is an important cause of early and late morbidity and mortality in breast cancer patients. Left ventricular (LV) function is assessed for patients receiving anthracycline-based chemotherapy to identify cardiotoxicity. However, animal studies suggest that right ventricular (RV) function may be a more sensitive measure to detect LV dysfunction. The purpose of this pilot study was to determine if breast cancer patients undergoing anthracycline-based chemotherapy experience RV dysfunction.

Methods: Forty-nine breast cancer patients undergoing anthracycline-based chemotherapy at the Ottawa Hospital between November 2007 and March 2013 and who had 2 echocardiograms performed at least 3 months apart were retrospectively identified. Right atrial area (RAA), right ventricular fractional area change (RV FAC) and RV longitudinal strain of the free wall (RV LSFW) were evaluated according to the American Society of Echocardiography guidelines.

Results: The majority (48/49) of patients were females with an average age of 53.4 (95% CI: 50.1–56.7 years). From baseline to follow-up study, average LV ejection fraction (LVEF) decreased from 62.22 (95% CI: 59.1–65.4) to 57.4% (95% CI: 54.0–60.9) (P=0.04). During the same time period, the mean RAA increased from 12.1 cm² (95% CI: 11.1–13.0 cm²) to 13.8 cm² (95% CI: 12.7–14.9 cm²) (P=0.02), mean RV FAC decreased (P=0.01) from 48.3% (95% CI: 44.8–51.74) to 42.1% (95% CI: 38.5–45.6%), and mean RV LSFW worsened from −16.2% (95% CI: −18.1 to −14.4%) to −13.81% (95% CI: −15.1 to −12.5%) (P=0.04).

Conclusion: This study demonstrates that breast cancer patients receiving anthracycline-based chemotherapy experience adverse effects on both right atrial size and RV function. Further studies are required to determine the impact of these adverse effects on right heart function and whether this represents an earlier marker of cardiotoxicity.

Key Words

- right heart function
- chemotherapy
- cardiotoxicity
- echocardiography
Introduction

Breast cancer patients undergoing chemotherapy have an increased risk of developing cardiovascular complications including heart failure (1, 2). Of the various chemotherapeutic agents used in breast cancer treatment, anthracyclines and their related compounds are some of the most frequently implicated agents (1, 2). Anthracycline-based chemotherapy is associated with a dose-dependent risk of congestive heart failure that can occur years after completion of chemotherapy. The clinical impact of this latent toxicity can be significant. A study carried out in older women (>66 years of age) who had been treated for breast cancer demonstrated a higher risk of death from cardiovascular disease than recurrence of breast cancer 7–8 years after completion of breast cancer treatment (2). Although a number of studies have reported the adverse impact of anthracycline-based agents on left ventricular (LV) systolic and diastolic function, limited data exists on their impact on right ventricular (RV) function. Preliminary human and animal studies have suggested that the detrimental/toxic effect of doxorubicin provokes global cardiac injury that extends to both the left and right ventricles (3, 4, 5). Importantly, RV function is a strong incremental predictor of prognosis in patients with LV systolic dysfunction and various LV pathologies (6, 7). The evaluation of RV function using traditional echocardiographic methods, as well as novel methods such as deformation imaging (strain, strain rate imaging), as recommended in the recent multimodality guidelines to detect subclinical LV dysfunction, may provide evidence of associated right ventricular cardiotoxicity (8).

Materials and methods

Using the University of Ottawa Local Breast Cancer Registry, we retrospectively identified 49 patients with early-stage human epidermal growth factor receptor 2 negative breast cancer (stage I–III) who underwent anthracycline-based chemotherapy at the Ottawa Hospital between November 2007 and March 2013. All of these 49 patients had undergone at least two echocardiograms performed at least 3 months apart. The majority of patients (i.e., 80%) had undergone echocardiogram before the completion of first cycle of chemotherapy (mean: 30 days; 95% CI: 3–57 days before chemotherapy). All patients had their follow-up echocardiography after the completion of chemotherapy cycle (mean: 125 days; 95% CI: 107–142 days). The Breast Cancer Registry was approved by the Human Research Ethics Board, and all patients provided written informed consent for the use of their data.

Echocardiography and image analysis

Comprehensive echocardiographic examinations were carried out according to the standard recommendations of the American Society of Echocardiography (ASE) (9, 10). All echocardiographic images were digitally stored and conventional echocardiographic parameters were measured. The parameters of cardiac structure and function were measured as per the guidelines of ASE (9, 10).

Right atrial area (RAA) measurements were performed in the apical four-chamber view. RAA was estimated by planimetry at the end of ventricular systole (largest atrial volume), tracing the RA endocardium from the lateral aspect of the tricuspid annulus to the septal aspect, excluding the area between the leaflets and annulus, and the right atrial appendage.

In our study, we hypothesized that breast cancer patients undergoing anthracycline-based chemotherapy would show evidence of right ventricular dysfunction identifiable using transthoracic echocardiography and currently available echocardiographic techniques.

Figure 1
Panel A is a pre-chemotherapy image depicting normal right ventricle free wall longitudinal strain. Panel B is a post-chemotherapy image from the same patient showing reduced right ventricle free wall longitudinal strain.
the percentage change in the RV end-diastolic and end-systolic areas.

RV longitudinal strain of the free wall (RV LSFW) was measured offline using speckle-tracking method and dedicated TomTec software (TomTec Imaging Systems, Unterschleissheim, Germany). In brief, the endocardial border of the RV was manually traced (approximately 10 points) over 1 frame, and endocardial borders were automatically tracked throughout the cardiac cycles by the software. The software determines myocardial velocity as the ratio between frame-to-frame displacement of the speckles and the time interval, and derives the systolic longitudinal strain. Longitudinal strain (LS) of the RV free wall was measured as the average of three segmental strain values (base, mid and apex) (Fig. 1).

Images were reviewed and analyzed offline by two independent observers blinded to the clinical characteristics of the study population. Reproducibility analysis for right heart parameters was performed in a subset of patients ($n=10$) and intra-class correlation coefficient value was 0.81 (95% CI: 0.58–0.91).

### Statistical analysis

MedCalc for Windows version 12.0 (MedCalc Software, Ostend, Belgium) was used for analysis of the data. For the continuous variables, parametric test conditions were first tested. The Shapiro–Wilk test was used to determine whether the continuous variables were normally distributed. Descriptive statistics were shown as mean ± s.d. or median (minimum–maximum), where appropriate. To compare the echocardiography variables, paired $t$-test was used and statistical significance was defined as two-tailed probability value of $P<0.05$.

### Results

#### Baseline characteristics

Baseline characteristics of study population are provided in **Table 1**. The mean age was 53.4 years (95% CI: 50.2–56.6 years) and the majority of patients had no pre-existing cardiovascular disease. All but one ($n=48$) patients were female and most were nonsmokers and had no history of hypertension or hyperlipidemia. A total of 15 patients received doxorubicin-based chemotherapy (doxorubicin/cyclophosphamide every 3 weeks × 4 cycles ± paclitaxel). The mean total dose of doxorubicin

| Table 1 | Baseline characteristics of study population. |
|---------|---------------------------------------------|
| $n=49$  |                                             |
| Age (years) | 53.4±3.3 (50.1–56.7) |
| Women    | 48 (98.0%) |
| Body mass index (kg/m²) | 25.9±1.3 (24.6–27.2) |
| Cardiac risk factors  |
| Smoker/ex-smoker | 21 (42.9%) |
| Hypertension | 12 (24.5%) |
| Dyslipidemia | 7 (14.3 %) |
| Diabetes | 7 (14.3%) |
| Family history of coronary artery disease | 2 (4.1%) |
| Cardiac history  |
| Prior coronary artery disease | 2 (4.1%) |

### Table 2  | Echocardiography parameters. |

|                                | Baseline | Follow-up | Significance $P$ |
|--------------------------------|----------|-----------|------------------|
| LVEF                           | 62.2% (95% CI: 59.1–65.4) | 57.4% (95% CI: 54.0–60.9) | 0.04 |
| LV GLS                         | $-15.4$ (95% CI: $-16.3$ to $-14.5$) | $-12.8$ (95% CI: $-13.8$ to $-11.9$) | $<0.0001$ |
| LV diastole (cm)               | 4.6 (95% CI: 4.5–4.7) | 4.9 (95% CI: 4.8–5.1) | $<0.0001$ |
| LV systole (cm)                | 3.0 (95% CI: 2.9–3.2) | 4.0 (95% CI: 2.9–5.1) | 0.10 |
| LV septum (cm)                 | 0.84 (95% CI: 0.80–0.89) | 0.84 (95% CI: 0.80–0.87) | 0.75 |
| Posterior wall (cm)            | 0.87 (95% CI: 0.83–0.91) | 0.87 (95% CI: 0.83–0.90) | 0.96 |
| Fractional shortening (%)      | 33.9 (95% CI: 31.8–36.0) | 30.3 (95% CI: 27.8–32.7) | 0.003 |
| Mitral valve E Max velocity (cm/s) | 74.9 (95% CI: 70.7–79.2) | 73.8 (95% CI: 69.0–78.6) | 0.60 |
| Mitral valve A Max velocity (cm/s) | 71.1 (95% CI: 64.6–77.7) | 73.8 (95% CI: 68.4–79.1) | 0.20 |
| Mitral valve E/A               | 1.14 (95% CI: 1.02–1.30) | 1.08 (95% CI: 0.95–1.21) | 0.15 |
| Left atrium (cm)               | 3.3 (95% CI: 3.1–3.5) | 3.4 (95% CI: 3.2–3.5) | 0.12 |
| Aortic root (cm)               | 2.8 (95% CI: 2.6–2.9) | 2.9 (95% CI: 2.7–3.0) | 0.14 |
| RV FAC                         | 48.3% (95% CI: 44.8–51.7) | 42.1% (95% CI: 38.5–45.6%) | 0.01 |
| RAA                           | 12.7 cm² (95% CI: 11.1–13.1 cm²) | 13.8 cm² (95% CI: 12.7–14.9 cm²) | 0.02 |
| LS RVFW                        | $-16.2$% (95% CI: $-18.1$ to $-14.4$ %) | $-13.8$% (95% CI: $-15.1$ to $-12.5$ %) | 0.04 |
| Heart rate (beats/min)         | 83 (95% CI: 74–92) | 79 (95% CI: 74–84) | 0.32 |

LS RVFW, longitudinal strain of the RV free wall; LV GLS, longitudinal strain of the LV; LVEF, LV ejection fraction; RAA, right atrial area; RV FAC, right ventricular fractional area change.
was 232 mg/m$^2$ (95% CI: 214.84–249.16 mg/m$^2$). A total of 34 patients received epirubicin-containing chemotherapy (fluorouracil/epirubicin/cyclophosphamide every 3 weeks ± docetaxel). The average total dose of epirubicin was 294.12 mg/m$^2$ (95% CI: 285.78–302.46 mg/m$^2$).

**Echocardiographic variables**

The average LV ejection fraction (LVEF) decreased from 62.2% (95% CI: 59.1–65.4) at their first echocardiogram to 57.4% (95% CI: 54.0–60.9) on follow-up echocardiogram ($P = 0.04$) (Table 2). Similarly, the mean LV global LS decreased from $-15.4\%$ (95% CI: $-16.3$ to $-14.5$) to $-12.8\%$ (95% CI: $-13.8$ to $-11.9$) on follow-up ($P < 0.0001$).

Mean RAA significantly increased from 12.1 cm$^2$ (95% CI: 11.1–13.0 cm$^2$) to 13.8 cm$^2$ on follow-up echocardiogram (95% CI: 12.7–14.9 cm$^2$) ($P = 0.02$). Mean RV FAC significantly decreased from 48.3% (95% CI: 44.8–51.7) to 42.1% on follow-up ($P = 0.01$). Mean RV LSFW worsened from $-16.2\%$ (95% CI: $-18.1$ to $-14.4\%$) to $-13.8\%$ on follow-up (95% CI: $-15.1$ to $-12.5\%$) ($P = 0.04$).

**Discussion**

Whereas previous studies involving anthracycline-based chemotherapy in breast cancer patients have identified clinical and subclinical LV dysfunction, we have demonstrated that anthracycline-based chemotherapy can adversely affect right heart function. Moreover, in this study we have identified a previously unreported abnormality in RV function (RV LSFW) evident in breast cancer patients receiving anthracycline-based chemotherapy using myocardial deformation parameters, the latter considered an important marker of subclinical dysfunction for the left ventricle (8).

**Right heart assessment and its implications**

It is increasingly recognized that RV function plays an important role in determining prognosis in conditions that have typically been regarded as largely related to LV pathologies, including congestive heart failure and coronary artery disease (6, 7, 11, 12, 13). Despite advancement in echocardiographic techniques, the assessment of the right ventricle by conventional two-dimensional echocardiography remains challenging due to its complex shape and systolic mechanics (9).

Right atrial assessment is of clinical importance as its enlargement can reflect abnormalities in RV function, and right atrial enlargement has been shown to be strongly associated with adverse clinical outcomes (14, 15). We measured RAA in our study as it is considered an accurate and reliable technique for evaluating right atrial size (9, 14).

Of the many different echocardiographic indices of RV function, RVFAC is the most commonly used two-dimensional method to assess RV function (9). It is considered to be a robust predictor of heart failure, sudden death, stroke and mortality in patients with right and left heart conditions (16, 17, 18). However, like LVEF, RVFAC change may be a late manifestation of RV dysfunction. In the setting of cardiotoxicity from cancer therapy, early detection of subclinical cardiotoxicity is desirable to permit modification of cancer treatment or optimization of cardiac function.

Deformation imaging (strain or strain rate imaging) was initially developed to measure LV mechanics. However, recent studies have established its usefulness for the assessment of the RV in disease states where RV function can be adversely affected (19, 20, 21, 22). As the bulk of RV muscle fibers run longitudinally, longitudinal shortening assessed by strain imaging has the potential to reveal early stages of myocardial dysfunction not evident on routine RV parameters (23).

**Mechanism of right heart abnormalities**

In our study we found that RAA, RVFAC and RV LSFW (in addition to LVEF) were adversely affected by anthracycline-based chemotherapy. Previous histological studies have indicated that cardiotoxic damage is more prominent in the sub-endocardial part of the cardiac walls (26). Intuitively, a thinner RV may be more sensitive to the toxic effects of chemotherapy compared with the thicker muscular LV, although data to support this
premise are limited. Prospective nonhuman studies with histological analysis to test whether the right ventricle is involved at an earlier time than the left ventricle would lend support to this hypothesis. We have identified both LV and RV dysfunction in our patients, but we are unable to determine if the RV is more sensitive to the cardiotoxic effects.

RV cardiotoxicity as a result of chemotherapy has not been adequately studied and previous studies have revealed divergent results. Belham et al. observed no change in RV myocardial performance index when patients were evaluated following administration of low-dose anthracycline (27). Similarly, Cottin et al. reported no alterations in the RV function at 1 and 12 months after anthracycline therapy using multigated acquisitions (28). However, Yildirim et al. reported abnormalities in the RV tissue Doppler velocities at rest and during dobutamine stress echocardiography following anthracycline administration (29) and Tanindi et al. reported a decrease in the RVFAC during chemotherapy in a study carried out in 37 patients (3). Our results reveal similar findings and add to the growing evidence by demonstrating abnormalities in RV function using deformation imaging – an important technique to identify subclinical LV dysfunction that has been incorporated into the most recent multimodality imaging guidelines to assess cardio-oncologic patients (8).

Limitations

Because of the retrospective aspect of this study we were unable to evaluate the utility of RV tissue Doppler and tricuspid annular plane septal excursion measurements as they were not systematically recorded. Another limitation of the study is the absence of cardiac biomarkers as they were not collected. Due to the limited number of patients in our study, we were unable to determine if the RV functional impairment was independent of or preceded a fall in LV function. However, this study clearly demonstrates, using multiple measures, that the RV may be adversely impacted by anthracycline-based chemotherapy regimens. Further studies will be required to evaluate the potential of RV parameters to identify cardiotoxicity before the current LV parameters. To determine the impact of these RV parameters on patient prognosis, a larger prospective multicenter study with a more objective comparison method, such as cardiac magnetic resonance imaging, will be needed to confirm these correlations and the clinical impacts of our results.

Conclusions

Our pilot study confirms that the right side of the heart is adversely affected in breast cancer patients undergoing anthracycline-based chemotherapy. Future work should be conducted to determine if right heart dysfunction precedes left heart abnormalities, potentially permitting earlier detection and possible intervention strategies to prevent chemotherapy-induced cardiac dysfunction in this population.

Declaration of interest

S D is on the advisory board and receives honoraria from Hoffman-La Roche, Amgen, Eisai, and Pfizer. There are no other conflicts of interest for any other authors.

Funding

Dr Girish Dwivedi is supported by a CIHR salary support award.

Ethics statement

The study was approved by Ottawa Health Science Network-REB (OHSN-REB).

References

1. Carver JR, Shapiro CL, Nq A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughan DJ & for the ASCO Cancer Survivorship Expert Panel 2007 ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of Clinical Oncology 25 3991–4008. (doi:10.1200/JCO.2007.10.9777)
2. Suter TM & Ewer MS 2013 Cancer drugs and the heart: importance and management. European Heart Journal 34 1102–1111. (doi:10.1093/eurheartj/ehr181)
3. Tanindi A, Demirici U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, Yalcin R & Benekli M 2011 Assessment of right ventricular functions during cancer chemotherapy. European Journal of Echocardiography 12 834–840. (doi:10.1093/ejechocard/jer142)
4. Krain SN, Krandycheva VV, Streilkoiva MV, Tsytetskova AS & Shimakov DN 2010 Doxorubicin-induced changes of ventricular repolarization heterogeneity: results of a chronic rat study. Cardiovascular Toxicology 12 312–317. (doi:10.1007/s12012-012-9172-0)
5. Oliveira GH, Dupont M, Nafeut D, Myers SL, Yuan Y, Tang WH, Gonzalez-Stawinski G, Young JB, Taylor DO & Starling RC 2014 Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support), Journal of the American College of Cardiology 63 240–248. (doi:10.1016/j.jacc.2013.09.040)
6. Ghiu S, Gavazzi A, Campana C, Inserna C, Klersy C, Sebastiani R, Arbustini E, Recusani F & Tavazzi L 2001 Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. Journal of the
American College of Cardiology 37 183–188. (doi:10.1016/S0735-1097(00)1102-5)

7 Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, et al. 2008 Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). American Journal of Cardiology 101 607–612. (doi:10.1016/j.amjcard.2007.09.115)

8 Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Gnanme J, Sebag IA, Agler DA, Badano LP, et al. 2014 Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography 27 911–939. (doi:10.1016/j.echo.2014.07.012)

9 Rudski LG, Lai WW, Afilalo J, Hua I, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK & Schiller NB 2010 Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. Journal of the American Society of Echocardiography 23 685–713. (doi:10.1016/j.echo.2010.05.010)

10 Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. 2015 Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography 28 1–39. (doi:10.1016/j.echo.2014.10.003)

11 Gulati A, Ismail TF, Jabbour A, Alpendurada F, Guha K, Ismail NA, Raza S, Khwaja J, Brown TD, Morarji K, et al. 2013 The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation 128 1623–1633. (doi:10.1161/CIRCULATIONAHA.113.002518)

12 Motoki H, Borowski AG, Shrestha K, Hu B, Kusunose K, Troughton RW, Tang WH & Klein Al 2014 Right ventricular global longitudinal strain provides prognostic value incremental to left ventricular ejection fraction in patients with heart failure. Journal of the American Society of Echocardiography 27 726–732. (doi:10.1016/j.echo.2014.02.007)

13 Antoni ML, Schepetong RW, Atary JZ, Boersma E, Holman ER, van der Wall EE, Schalij MJ & Bax JJ 2010 Prognostic value of right ventricular function in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Circulation Cardiovascular Imaging 3 264–271. (doi:10.1161/CIRCIMAGING.109.14366)

14 Grapsa J, Gibbs JS, Cabrita IZ, Watson GF, Pavlopoulos H, Dawson D, Gin-Sing W, Howard LS & Nihoyannopoulos P 2012 The association of clinical outcome with right atrial and ventricular remodelling in patients with pulmonary arterial hypertension: study with real-time three-dimensional echocardiography. European Heart Journal Cardiovascular Imaging 13 666–672. (doi:10.1093/ehjci/jes003)

15 Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hall NS, Summer WR, de Boislalc B, et al. 2002 Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. Journal of the American College of Cardiology 39 1214–1219. (doi:10.1016/S0735-1097(02)01744-8)

16 Nass N, McConnell MV, Goldhaber SZ, Chyu S & Solomon SD 1999 Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. American Journal of Cardiology 83 804–806. (doi:10.1016/S0002-9149(98)01000-5)

17 Zornoza LF, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL, Lamas GA, Plappert T, Rouleau JR, Moyé LA, Lewis SJ, et al. 2002 Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. Journal of the American College of Cardiology 39 1450–1455. (doi:10.1016/S0735-1097(02)01804-1)

18 Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, et al. 2008 Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). American Journal of Cardiology 101 607–612. (doi:10.1016/j.amjcard.2007.09.115)

19 Verhaert D, Mullens W, Borowski A, Popovic ZB, Curtin RJ, Thomas JD & Tang WH 2010 Right ventricular response to intensive medical therapy in advanced decompensated heart failure. Circulation Heart Failure 3 340–346. (doi:10.1161/ CIRCHEARTFAILURE.109.900134)

20 Prat B, McCulloch ML & Zoghbi WA 2006 Evaluation of global and regional right ventricular systolic function in patients with pulmonary hypertension using a novel speckle tracking method. European Journal of Echocardiography 98 699–704. (doi:10.1016/j.euje.2006.03.056)

21 La Gerche A & Roberts TJ 2015 Straining the RV to predict the future. JACC: Cardiovascular Imaging 8 170–171. (doi:10.1016/j.jcmg.2014.11.006)

22 Park SJ, Park J-H, Lee HS, Park YK, Park Y, Kim YJ, Lee JH, Choi SW, Jeong JO, et al. 2015 Impaired RV global longitudinal strain is associated with poor long-term clinical outcomes in patients with acute inferior STEMI. JACC: Cardiovascular Imaging 8 161–169. (doi:10.1016/j.jcmg.2014.10.011)

23 Tantri H, Daya SK, Nasir K, Bomma C, Lima JA, Calkins H & Blumke DA 2006 Normal reference values for the adult right ventricle by magnetic resonance imaging. American Journal of Cardiology 98 1660–1664. (doi:10.1016/j.amjcard.2006.07.049)

24 Park JH, Negishi K, Kwon DH, Popovic ZB, Grimm RA & Marwick TH 2014 Validation of global longitudinal strain and strain rate as reliable markers of right ventricular dysfunction: comparison with cardiac magnetic resonance and outcome. Journal of Cardiovascular Ultrasound 22 113–120. (doi:10.4250/jcu.2014.22.3.113)

25 Park JH, Park MM, Farha S, Sharp J, Lundgren E, Comhair S, Tang WH, Erzurum SC & Thomas JD 2015 Impaired global right ventricular longitudinal strain predicts long-term adverse outcomes in patients with pulmonary arterial hypertension. Journal of Cardiovascular Ultrasound 23 91–99. (doi:10.4250/jcu.2015.23.2.91)

26 Llesy SF, Milej C, Gonzalez Flecha BS & Boveris A 1990 Myocardial chemiluminescence and morphology. Free Radical Biology and Medicine 8 259–264. (doi:10.1016/0891-5849(90)90071-P)

27 Belham M, Kruger A & Pritchard C 2006 The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. Journal of the American Society of Echocardiography 19 206–210. (doi:10.1016/j.echo.2005.08.018)

28 Cottin Y, Touzery C, Coubert D, Ribeiro D, Cohen M, Toubeau M, Louis P, Wolf E & Brunotte F 1996 Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. European Journal of Nuclear Medicine 23 511–516. (doi:10.1007/BF00335384)

29 Yildirim A, Sedef Tunaoglu F, Pinarli FG, Ilhan M, Oguz A, Karadeniz C, Olguntürk R, Oguz D & Kula S 2010 Early diagnosis of anthracycline toxicity in asymptomatic long-term survivors: dobutamine stress echocardiography and tissue Doppler velocities in normal and abnormal myocardial wall motion. European Journal of Echocardiography 11 814–822. (doi:10.1093/echocardiography/jeq071)

Received in final form 14 July 2016
Accepted 22 July 2016
Accepted Preprint published online 25 July 2016